The Top 10 Best-Selling Drugs Of 2020
Humira Tops The $100bn List
AbbVie’s Humira easily retained its lead in 2020 with $20.3bn in sales. Gilead Sciences’ HIV triple combo Biktarvy was the fastest climber, entering the top 10 in eighth place after 53.2% growth in a year, while Avastin, Enbrel and Rituxan fell out of the list.
You may also be interested in...
Drugs for inflammatory conditions and cancer drove the increase in spending among the pharmacy benefit manager’s commercial plans, according to a drug trend report from Cigna's Evernorth.
A 10-year review of the top 20 biopharmaceutical companies by revenue found that portfolio focus, not therapeutic area diversity, delivered the strongest growth rates.
Blockbuster status has long been the ultimate goal of drug development, defined as a sales potential of more than $1bn. The economics of drug development, and in fact of the entire biopharma industry, very much rely on these few gems that provide the returns to compensate for the long development pathway and often several billion dollars of investment per new molecular entity.